• Maze Therapeutics announced positive topline data from the Phase 2 open-label HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease.
• At week 12, treatment with MZE829 drove a 35.6% mean uACR reduction, and 50% of patients achieved a greater than 30% reduction in uACR.
• Among AMKD patients with focal segmental glomerulosclerosis, uACR fell 61.8% on average, while non-diabetic AMKD patients saw a 48.6% mean reduction from baseline.
• In the safety-evaluable population (n=15), no serious adverse events or severe treatment-related adverse events were observed, and the most common treatment-related adverse events were headache (n=2) and diarrhea (n=2).
• The company said it expects to continue enrollment and advance MZE829 into a pivotal program, with HORIZON data planned for presentation at a future medical conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250700PRIMZONEFULLFEED9678245) on March 25, 2026, and is solely responsible for the information contained therein.